(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -4.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Biontech Se's revenue in 2026 is $3,011,363,636.On average, 25 Wall Street analysts forecast BNTX's revenue for 2026 to be $557,609,795,505, with the lowest BNTX revenue forecast at $492,618,540,428, and the highest BNTX revenue forecast at $682,028,851,917. On average, 23 Wall Street analysts forecast BNTX's revenue for 2027 to be $578,346,304,907, with the lowest BNTX revenue forecast at $357,578,345,054, and the highest BNTX revenue forecast at $795,826,769,367.
In 2028, BNTX is forecast to generate $678,994,240,785 in revenue, with the lowest revenue forecast at $340,635,099,567 and the highest revenue forecast at $891,164,135,764.